Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Different Materials Are Forming the Future of 3D Printing

Hobbyists and artists have utilized a wide variety of materials in their 3D printing experimentation, from ceramics to even sugar and sand.[1] The tight control and consistency that 3D printing offers users has so far encouraged experimentation in numerous sectors. As 3D printing begins to disrupt commercial industries such as construction, a select few materials…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Hobbyists and artists have utilized a wide variety of materials in their 3D printing experimentation, from ceramics to even sugar and sand.[1] The tight control and consistency that 3D printing offers users has so far encouraged experimentation in numerous sectors. As 3D printing begins to disrupt commercial industries such as construction, a select few materials have emerged as reliable, flexible, and cost-effective.

3D printing has numerous uses at nearly every stage of the construction process. Among the earliest adopters of 3D printing tech relied on it for detailed, complex, and entirely three-dimensional prototype models that used most of the same materials the final product would.[2] This “additive manufacturing” (AM) evolved to allow for onsite printing, slashing labor costs and safety concerns.[3] These demonstrations have rapidly driven up the frequency of 3D printing applications in fields like healthcare and aircraft manufacturing as well as construction. So far, metals, plastics, and ceramics have come to dominate these emerging materials markets.

Plastics and polymers are among the most widely used materials for creating small prototypes to printing affordable housing in developing countries. Acrylonitrile Butadiene Styrene (ABS), Polylactic Acid (PLA), and the polyamides PA11/PA12 are the foremost polymers being pushed by European firms such as France’s Arkema SA and Germany’s Evonik AG.[4] A specialized form of concrete that requires a supersize printer will set as it’s being printed and, due to its composite nature, is much more supportive than conventional materials.[5]

An important aspect of this burgeoning market is less the type of material itself and more the form it takes. Powder-based AM calls for powder forms of metals like titanium as well as plastics like ABS and PLA. New patents for the creation of these powders are pending while manufacturers expand their capacity to keep up with growing global demand.[6] New materials like thermoplastic filaments, resins that are photosensitive, and more are in development now, with a whole new set of applications likely to emerge.

Though the 3D printing artists of the world may not be the ones to build new homes, their experimental instincts have no doubt influenced manufacturers to follow suit. 3D printing remains a nascent technology with significant room for growth.

For the latest news, videos, and podcasts in the AEC Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @AECMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

[1] https://architizer.com/blog/inspiration/industry/data-clay/

[2] https://3dprintingindustry.com/news/top-10-3d-printed-construction-innovations-83578/

[3] https://www.researchgate.net/publication/303749537_Processing_and_properties_of_construction_materials_for_3D_printing

[4] https://blog.marketresearch.com/5-key-trends-in-3d-printing-materials

[5] https://www.forbes.com/sites/sap/2018/08/20/how-3d-printing-is-disrupting-the-materials-building-industry/#d1b131c1fdc7

[6] https://www.idtechex.com/research/reports/3d-printing-materials-2018-2028-technology-and-market-analysis-000583.asp

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512